Publication | Closed Access

Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort

Cardiovascular EpidemiologyCardiovascular DiseaseLifelong TherapyCardiovascular PharmacologyPharmacotherapyCost EffectivenessPublic HealthMedicineAtherosclerosisEpidemiologyLudwigshafen RiskCoronary Artery Disease